Same past mistakes of failed CEOs who held to tight.The CEO by holding to tight to his creation will assure an eventual failure of StageZero because it will let competitors catch up. Seen it before with other stocks. The CEO has failed to get involved the big players who could have pushed Aristotle market wide and make their multi-cancer panel for simultaneously screening 10 cancers known as the first cancer screening test in the market.
The acquisition of two clinics will make Aristotle known by word of mouth only. How long will it take before their competitors will catch up and make them obsolete because they chose to go small time?
Is he repeating the same marketing and business decisions for Colorectal Cancer test they created? Not much revenues from it.